BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang H, Tseng T, Liu J, Lee M, Liu C, Su T, Batrla-utermann R, Chan HL, Kao J, Chen C. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. Clinical Gastroenterology and Hepatology 2016;14:461-468.e2. [DOI: 10.1016/j.cgh.2015.10.033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu HC, Tseng JC, Lu LY, Hu JC, Chen YH, Hsu CL, Wu PC, Mar GY, Lin KH. Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy. Eur J Gastroenterol Hepatol 2021;33:107-13. [PMID: 32243344 DOI: 10.1097/MEG.0000000000001707] [Reference Citation Analysis]
2 Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang H. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
4 Jeon MY, Lee HW, Kim SU, Kim BK, Park JY, Kim DY, Han K, Ahn SH. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. Liver Int 2018;38:676-86. [DOI: 10.1111/liv.13583] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
5 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
6 Tseng T, Kao J. HBV markers for HCC prediction: Three heads are better than two? Journal of Hepatology 2017;67:203-4. [DOI: 10.1016/j.jhep.2017.03.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol 2017;11:999-1008. [PMID: 28965428 DOI: 10.1080/17474124.2017.1386554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
8 Thi Vo T, Poovorawan K, Charoen P, Soonthornworasiri N, Nontprasert A, Kittitrakul C, Phumratanaprapin W, Tangkijvanich P. Association between Hepatitis B Surface Antigen Levels and the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection: Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev 2019;20:2239-46. [PMID: 31450890 DOI: 10.31557/APJCP.2019.20.8.2239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
9 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
10 Chen CJ. Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. Gut. 2018;67:595-598. [PMID: 29367206 DOI: 10.1136/gutjnl-2017-315407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
11 Dusheiko G, Wang B, Carey I. HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy. Hepatol Int 2016;10:727-9. [DOI: 10.1007/s12072-016-9738-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
12 Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH, McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer 2020;147:2743-53. [PMID: 32406072 DOI: 10.1002/ijc.33051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Sherman M. How to improve HCC surveillance outcomes. JHEP Rep 2019;1:460-7. [PMID: 32039398 DOI: 10.1016/j.jhepr.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Thrift AP, Kanwal F, El-serag HB. Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clinical Gastroenterology and Hepatology 2016;14:1678-80. [DOI: 10.1016/j.cgh.2016.08.026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
15 Hsu YC, Tseng CH, Huang YT, Yang HI. Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. Semin Liver Dis 2021;41:285-97. [PMID: 34161993 DOI: 10.1055/s-0041-1730924] [Reference Citation Analysis]
16 Koshiol J, Argirion I, Liu Z, Kim Lam T, O'Brien TR, Yu K, McGlynn KA, Petrick JL, Pinto L, Chen CJ, Hildesheim A, Pfeiffer RM, Lee MH, Yang HI. Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. Aliment Pharmacol Ther 2021;54:833-42. [PMID: 34286851 DOI: 10.1111/apt.16524] [Reference Citation Analysis]
17 Chen CJ, You SL, Hsu WL, Yang HI, Lee MH, Chen HC, Chen YY, Liu J, Hu HH, Lin YJ, Chu YJ, Huang YT, Chiang CJ, Chien YC. Epidemiology of Virus Infection and Human Cancer. Recent Results Cancer Res 2021;217:13-45. [PMID: 33200360 DOI: 10.1007/978-3-030-57362-1_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]